Abeona director sells 2,000 shares for tax obligations

Abeona Therapeutics director Mark Alvino reported a small share sale to cover taxes.

Rhea-AI Filing Summary

Abeona Therapeutics director Mark Alvino reported a small share sale to cover taxes. On February 2, 2026, he sold 2,000 shares of common stock in Abeona Therapeutics at a weighted average price of $5.0906 per share.

The filing explains that the sale was made to satisfy tax obligations arising from the vesting of restricted stock awards, rather than as a discretionary portfolio decision. After this transaction, Alvino directly beneficially owned 84,065 shares of Abeona Therapeutics common stock, and no derivative securities were reported.

Insider Trade Summary

Net Seller: 2,000 shares

Net Sell 1 txn

Insider Alvino Mark

Role Director

Sold 2,000 shs ($10K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,000	$5.0906	$10K

Holdings After Transaction: Common Stock — 84,065 shares (Direct)

Footnotes (2)

1. F1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Abeona Therapeutics (ABEO) disclose for Mark Alvino?

Abeona Therapeutics disclosed that director Mark Alvino sold 2,000 shares of common stock on February 2, 2026. The sale was reported at a weighted average price of $5.0906 per share and was linked to tax obligations from restricted stock vesting.

Why did Abeona Therapeutics (ABEO) director Mark Alvino sell 2,000 shares?

The Form 4 states the sale was made to cover tax obligations from the vesting of restricted stock awards. This indicates the transaction was primarily for tax withholding purposes rather than a discretionary open-market liquidation of his Abeona Therapeutics common stock holdings.

How many Abeona Therapeutics (ABEO) shares does Mark Alvino own after the reported sale?

Following the reported transaction, director Mark Alvino directly beneficially owned 84,065 shares of Abeona Therapeutics common stock. This figure reflects his holdings after selling 2,000 shares on February 2, 2026 as disclosed in the Form 4 filing.

At what prices were the Abeona Therapeutics (ABEO) shares sold by Mark Alvino?

The filing reports a weighted average price of $5.0906 per share. Footnotes explain the 2,000 shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 per share, all within that disclosed price range.

Does the Abeona Therapeutics (ABEO) Form 4 report any derivative security transactions for Mark Alvino?

No derivative security transactions are listed for Table II in this Form 4. The filing only reports a non-derivative common stock sale of 2,000 shares by director Mark Alvino, with no options, warrants, or other derivative instruments disclosed.

Was the Abeona Therapeutics (ABEO) insider sale by Mark Alvino a direct or indirect holding?

The Form 4 identifies the 2,000-share sale as involving directly held common stock, marked with ownership code “D”. No nature of indirect beneficial ownership is disclosed, and there are no footnotes reallocating authority to any trust, LLC, or related entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alvino Mark

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		2,000	D	$5.0906(2)	84,065	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Mark Alvino	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.